ABBV vs LNSR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.
LNSR exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.63, indicating negative shareholder equity. The company is suffering from catastrophic profitability metrics, including an ROE of -1069.41% and an operating margin of -116.03%. Despite a 'strong_buy' analyst consensus from a very small sample (2 analysts), the fundamental data shows declining revenue (-4.20% YoY) and a consistent failure to meet earnings estimates (0/4 beats in the last year). The technical trend is aggressively bearish, with a 51.6% price collapse in the last month alone.
Compare Another Pair
Related Comparisons
ABBV vs LNSR: Head-to-Head Comparison
This page compares AbbVie Inc. (ABBV) and LENSAR, Inc. (LNSR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.